2,3-二氯-6-甲氧基苯甲醛 | 936249-28-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,3-二氯-6-甲氧基苯甲醛
• 英文名称: 2,3-dichloro-6-methoxybenzaldehyde
• CAS: 936249-28-4
• 化学式: C₈H₆Cl₂O₂
• 分子量: 205.04
• InChiKey: LKRDOTPHEHYNEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,3-二氯-6-甲氧基苯甲醛 在 sodium tetrahydroborate 、 sodium hydride 、 二异丁基氢化铝 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， 生成 [2-(2,3-dichloro-6-methoxyphenyl)cyclopropyl]methanol
  参考文献：
  名称：

  Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models

  摘要：

  A series of novel compounds with two halogen substituents have been designed and synthesized to further optimize the 2-phenylcyclopropylmethylamine scaffold in the quest for drug-like 5-HT2C agonists. Compound (+)-22a was identified as a potent 5-HT2C receptor agonist, with good selectivity against the 5-HT2B and the 5-HT2A receptors. ADMET assays showed that compound (+)-22a possessed desirable properties in terms of its microsomal stability, and CYP and hERG inhibition, along with an excellent brain penetration profile. Evaluation of (+)-22a in animal models of schizophrenia-related behaviors revealed that it had a desirable activity profile, as it reduced d-amphetamine-stimulated hyperlocomotion in the open field test, it restored d-amphetamine-disrupted prepulse inhibition, it induced cognitive improvements in the novel object recognition memory test in NR1-KD animals, and it produced very little catalepsy relative to haloperidol. These data support the further development of (+)-22a as a drug candidate for the treatment of schizophrenia.

  DOI：

  10.1021/acs.jmedchem.5b01153
• 作为产物：
  描述：

  N,N-二甲基甲酰胺 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.5h， 生成 2,3-二氯-6-甲氧基苯甲醛
  参考文献：
  名称：

  Pyrazine Derivatives

  摘要：

  本发明涉及公式化合物及其药用可接受盐和溶剂，用于制备该化合物的过程，用于制备的中间体，含有这种化合物的组合物以及用于治疗疼痛的这种化合物的用途。

  公开号：

  US20070105872A1

文献信息

• [EN] CYCLOPROPYLMETHANAMINES AS SELECTIVE 5-HT(2C) RECEPTOR AGONISTS<br/>[FR] CYCLOPROPYLMÉTHANAMINES UTILISÉES COMME AGONISTES SÉLECTIFS DES RÉCEPTEURS 5-HT(2C)
  申请人：UNIV ILLINOIS

  公开号：WO2016123164A1

  公开（公告）日：2016-08-04

  Disclosed are 2-phenyl-cyclopropylmethanamines which are selective 5-HT(2C) receptor agonists and are used in the treatments of diseases and conditions wherein modulation of 5-HT(2C) receptors provides a benefit, such as obesity and psychiatric disorders.

  揭示了一种选择性5-HT(2C)受体激动剂2-苯基环丙基甲胺，用于治疗疾病和病况，其中调节5-HT(2C)受体能够带来益处，如肥胖和精神障碍。
• Amino substituted pyrazine derivatives for the treatment of pain
  申请人：Pfizer Inc.

  公开号：US07572797B2

  公开（公告）日：2009-08-11

  The present invention relates to compounds of the formula and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds for the treatment of pain.

  本发明涉及公式化合物及其药学上可接受的盐和溶剂化物，以及制备、制备中间体和含有这种化合物的组合物的过程，以及这种化合物用于治疗疼痛的用途。
• Cyclopropylmethanamines as selective 5-HT(2C) receptor agonists
  申请人：THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

  公开号：US10407381B2

  公开（公告）日：2019-09-10

  Disclosed are 2-phenyl-cyclopropylmethanamines which are selective 5-HT(2C) receptor agonists and are used in the treatments of diseases and conditions wherein modulation of 5-HT(2C) receptors provides a benefit, such as obesity and psychiatric disorders.

  所公开的 2-苯基-环丙基甲胺是选择性 5-HT（2C）受体激动剂，可用于治疗调节 5-HT（2C）受体可带来益处的疾病和病症，如肥胖症和精神疾病。
• PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN
  申请人：Pfizer Limited

  公开号：EP1945630A2

  公开（公告）日：2008-07-23
• CYCLOPROPYLMETHANAMINES AS SELECTIVE 5-HT(2C) RECEPTOR AGONISTS
  申请人：The Board of Trustees of the University of Illinois

  公开号：EP3250549B1

  公开（公告）日：2021-06-23